Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 4
1952 4
1953 4
1954 5
1955 3
1956 4
1958 2
1959 5
1960 3
1961 4
1962 12
1963 12
1964 17
1965 14
1966 21
1967 24
1968 21
1969 33
1970 32
1971 28
1972 22
1973 21
1974 25
1975 40
1976 25
1977 35
1978 53
1979 46
1980 53
1981 69
1982 50
1983 59
1984 53
1985 72
1986 79
1987 81
1988 89
1989 122
1990 123
1991 102
1992 108
1993 130
1994 121
1995 119
1996 120
1997 132
1998 154
1999 117
2000 128
2001 133
2002 148
2003 115
2004 161
2005 139
2006 146
2007 175
2008 156
2009 173
2010 174
2011 205
2012 216
2013 206
2014 235
2015 249
2016 258
2017 307
2018 259
2019 280
2020 392
2021 466
2022 423
2023 296
2024 269

Text availability

Article attribute

Article type

Publication date

Search Results

7,438 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y, Kimura T; ONCO DVT Study Investigators. Yamashita Y, et al. Among authors: mori k. Circulation. 2023 Nov 21;148(21):1665-1676. doi: 10.1161/CIRCULATIONAHA.123.066360. Epub 2023 Aug 28. Circulation. 2023. PMID: 37638968 Clinical Trial.
Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker.
Taylor MS, Connie W, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cheng WC, Heaps J, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Norden BL, Chait BT, Goggins M, Bhan I, Franses JW, Yang X, Taplin ME, Wang X, Christiani DC, Johnson BE, Meyerson M, Uppaluri R, Egloff AM, Denault EN, Spring LM, Wang TL, Shih IM, Jung E, Arora KS, Zukerberg LR, Yilmaz OH, Chi G, Matulonis UA, Song Y, Nieman L, Parikh AR, Strickland M, Corcoran RB, Mustelin T, Eng G, Yilmaz ÃH, Skates SJ, Rueda BR, Drapkin R, Klempner SJ, Deshpande V, Ting DT, Rout MP, LaCava J, Walt DR, Burns KH. Taylor MS, et al. Among authors: mori k. bioRxiv [Preprint]. 2023 Mar 17:2023.01.25.525462. doi: 10.1101/2023.01.25.525462. bioRxiv. 2023. Update in: Cancer Discov. 2023 Dec 12;13(12):2532-2547. doi: 10.1158/2159-8290.CD-23-0313. PMID: 36747644 Free PMC article. Updated. Preprint.
Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19.
Kawakami E, Saiki N, Yoneyama Y, Moriya C, Maezawa M, Kawamura S, Kinebuchi A, Kono T, Funata M, Sakoda A, Kondo S, Ebihara T, Matsumoto H, Togami Y, Ogura H, Sugihara F, Okuzaki D, Kojima T, Deguchi S, Vallee S, McQuade S, Islam R, Natarajan M, Ishigaki H, Nakayama M, Nguyen CT, Kitagawa Y, Wu Y, Mori K, Hishiki T, Takasaki T, Itoh Y, Takayama K, Nio Y, Takebe T. Kawakami E, et al. Among authors: mori k. Cell Stem Cell. 2023 Oct 5;30(10):1315-1330.e10. doi: 10.1016/j.stem.2023.09.001. Cell Stem Cell. 2023. PMID: 37802037
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.
Taylor MS, Wu C, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cajuso T, Cheng WC, Heaps JD, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Chait BT, Goggins MG, Bhan I, Franses JW, Yang X, Taplin ME, Wang X, Christiani DC, Johnson BE, Meyerson M, Uppaluri R, Egloff AM, Denault EN, Spring LM, Wang TL, Shih IM, Fairman JE, Jung E, Arora KS, Yilmaz OH, Cohen S, Sharova T, Chi G, Norden BL, Song Y, Nieman LT, Pappas L, Parikh AR, Strickland MR, Corcoran RB, Mustelin T, Eng G, Yilmaz ÖH, Matulonis UA, Chan AT, Skates SJ, Rueda BR, Drapkin R, Klempner SJ, Deshpande V, Ting DT, Rout MP, LaCava J, Walt DR, Burns KH. Taylor MS, et al. Among authors: mori k. Cancer Discov. 2023 Dec 12;13(12):2532-2547. doi: 10.1158/2159-8290.CD-23-0313. Cancer Discov. 2023. PMID: 37698949 Free PMC article.
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Tsujino T, et al. Among authors: mori k. Cancer Med. 2023 Oct;12(19):19414-19422. doi: 10.1002/cam4.6536. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706578 Free PMC article.
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Bekku K, Laukhtina E, Rajwa P, Quhal F, Pradere B, Fukuokaya W, Iwatani K, Murakami M, Bensalah K, Grünwald V, Schmidinger M, Shariat SF, Kimura T. Yanagisawa T, et al. Among authors: mori k. Cancer Immunol Immunother. 2024 Jan 30;73(2):38. doi: 10.1007/s00262-023-03621-1. Cancer Immunol Immunother. 2024. PMID: 38289361 Free PMC article. Review.
Genetic insights into ossification of the posterior longitudinal ligament of the spine.
Koike Y, Takahata M, Nakajima M, Otomo N, Suetsugu H, Liu X, Endo T, Imagama S, Kobayashi K, Kaito T, Kato S, Kawaguchi Y, Kanayama M, Sakai H, Tsuji T, Miyamoto T, Inose H, Yoshii T, Kashii M, Nakashima H, Ando K, Taniguchi Y, Takeuchi K, Ito S, Tomizuka K, Hikino K, Iwasaki Y, Kamatani Y, Maeda S, Nakajima H, Mori K, Seichi A, Fujibayashi S, Kanchiku T, Watanabe K, Tanaka T, Kida K, Kobayashi S, Takahashi M, Yamada K, Takuwa H, Lu HF, Niida S, Ozaki K, Momozawa Y; Genetic Study Group of Investigation Committee on Ossification of the Spinal Ligaments; Yamazaki M, Okawa A, Matsumoto M, Iwasaki N, Terao C, Ikegawa S. Koike Y, et al. Among authors: mori k. Elife. 2023 Jul 18;12:e86514. doi: 10.7554/eLife.86514. Elife. 2023. PMID: 37461309 Free PMC article.
Fibroblast-specific PRMT5 deficiency suppresses cardiac fibrosis and left ventricular dysfunction in male mice.
Katanasaka Y, Yabe H, Murata N, Sobukawa M, Sugiyama Y, Sato H, Honda H, Sunagawa Y, Funamoto M, Shimizu S, Shimizu K, Hamabe-Horiike T, Hawke P, Komiyama M, Mori K, Hasegawa K, Morimoto T. Katanasaka Y, et al. Among authors: mori k. Nat Commun. 2024 Mar 19;15(1):2472. doi: 10.1038/s41467-024-46711-z. Nat Commun. 2024. PMID: 38503742 Free PMC article.
Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.
Setsu G, Goto M, Ito K, Taira T, Miyamoto M, Watanabe T, Taniguchi T, Umezaki Y, Nakazawa Y, Uesugi S, Mori K, Horiuchi T, Obuchi W, Minami M, Shimada T, Wada C, Yoshida T, Higuchi S. Setsu G, et al. Among authors: mori k. Eur J Pharmacol. 2023 Dec 15;961:176184. doi: 10.1016/j.ejphar.2023.176184. Epub 2023 Nov 8. Eur J Pharmacol. 2023. PMID: 37944847
Matrix metalloproteinase-10 deficiency has protective effects against peritoneal inflammation and fibrosis via transcription factor NFκΒ pathway inhibition.
Ishimura T, Ishii A, Yamada H, Osaki K, Toda N, Mori KP, Ohno S, Kato Y, Handa T, Sugioka S, Ikushima A, Nishio H, Yanagita M, Yokoi H. Ishimura T, et al. Among authors: mori kp. Kidney Int. 2023 Nov;104(5):929-942. doi: 10.1016/j.kint.2023.08.010. Epub 2023 Aug 29. Kidney Int. 2023. PMID: 37652204
7,438 results